Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Viral Hepatitis Market Expected To Reach $20.84 Billion By 2030 At 4.7% CAGR

The global market for viral hepatitis has experienced consistent expansion, projected to increase from $16.77 billion in 2025 to $17.37 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.6%. This upward trajectory in the past can be linked to several key factors, including enhanced blood screening measures, broader access to vaccinations, the introduction of effective antiviral treatments, heightened public understanding of the disease, and the implementation of government-backed hepatitis initiatives.

The global viral hepatitis market is projected for consistent expansion over the coming years, reaching an estimated $20.85 billion by 2030 with a compound annual growth rate of 4.7%. This anticipated growth is fueled by a confluence of factors, including intensified efforts towards hepatitis elimination, increased funding for innovative antiviral treatments, broader availability of point-of-care diagnostic tools, greater utilization of combination therapies, and the acceleration of worldwide screening initiatives. Key developments expected to shape the market during this period involve the wider implementation of sophisticated antiviral approaches, a rise in the application of molecular diagnostic methods, a heightened emphasis on identifying the disease early, the expansion of immunization campaigns, and more robust oversight of patients with chronic hepatitis.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13028&type=smp

Viral Hepatitis Market Demand Drivers: What Is Fueling Industry Growth?

The increasing incidence of hepatitis is poised to stimulate the expansion of the viral hepatitis market. This condition, characterized by inflammation of the liver stemming from various infectious agents and non-infectious factors, can lead to significant health complications. Specifically, the hepatitis A, B, C, D, and E viruses are key culprits behind viral hepatitis, which manifests as liver inflammation and potential damage. To illustrate, ECDC data from April 2025 indicated that by 2023, 37,766 new diagnoses of hepatitis B virus (HBV) infection were reported across 30 EU/EEA Member States, translating to a crude rate of 8.1 cases per 100,000 individuals. Consequently, the escalating occurrence of hepatitis is anticipated to be a primary driver for the viral hepatitis market.

Viral Hepatitis Market Segment Landscape: Which Areas Lead Market Development?

The viral hepatitis market covered in this report is segmented –

1) By Disease Type: Hepatitis A, Hepatitis B, Hepatitis C, Other Disease Types

2) By Diagnosis: Liver Biopsy, Blood Tests, Imaging Tests, Other Diagnosis

3) By Treatment: Antiviral Drugs, Surgery, Vaccine, Immune Modulator Drugs, Other Treatments

4) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Hepatitis A: Acute Hepatitis A, Chronic Hepatitis A

2) By Hepatitis B: Acute Hepatitis B, Chronic Hepatitis B, Hepatitis B Carrier

3) By Hepatitis C: Acute Hepatitis C, Chronic Hepatitis C

4) By Other Disease Types: Hepatitis D, Hepatitis E

Viral Hepatitis Market Innovation Trends: Which Developments Are Transforming The Industry?

Key players within the viral hepatitis sector are prioritizing the integration of sophisticated immunoassay techniques, specifically automated, dual-marker immunoassays, with the aim of improving the early identification and management of the disease. These advanced diagnostic tools, referred to as automated, dual-marker immunoassays, are designed for in-vitro diagnostic purposes and possess the ability to identify both antigens and antibodies from a single patient sample. This capability facilitates near-instantaneous assessment of infection status, reduces the time frame for diagnosis, and boosts the efficiency of screening processes. As an illustration, in July of 2023, Roche Diagnostics India, a prominent Indian entity specializing in in-vitro diagnostics and laboratory automation, introduced Elecsys HCV Duo. This novel immunoassay is specifically engineered to detect the hepatitis C virus by simultaneously and independently identifying both HCV core antigen and anti-HCV antibodies within a single serum or plasma specimen. This innovation allows for a significantly earlier diagnosis of active HCV infection and is fully compatible with automated analysis systems, including the cobas e 402 and e 801 models. The Elecsys HCV Duo contributes to a more rapid diagnosis, quicker referral to treatment, simplified diagnostic procedures, and a lessened strain on healthcare infrastructures.

Viral Hepatitis Market Industry Leaders And Market Competition

Major companies operating in the viral hepatitis market are Pfizer Inc., Johnson & Johnson Co, F Hoffmann-La Roche AG, Merck & Co., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Hetero Drugs Ltd., Eisai Co. Ltd., Boehringer Ingelheim Group, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories, Zydus Lifescience Ltd., Glenmark Pharmaceuticals Ltd., Cipla Ltd., Torrent Pharmaceuticals Ltd., Otsuka Pharmaceutical Co. Ltd., Wockhardt Ltd.

Access The Complete Viral Hepatitis Market Report:

https://www.thebusinessresearchcompany.com/report/viral-hepatitis-global-market-report

Viral Hepatitis Market Global Footprint: Which Region Holds Market Leadership?

North Americawas the largest region in the viral hepatitis market in 2025. The regions covered in the viral hepatitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.